OKYO Pharma Limited has filed for Fast Track designation with the U.S. FDA for its drug urcosimod, aimed at treating neuropathic corneal pain, a painful eye condition currently lacking an FDA-approved ...

The U.S. Patent and Trademark Office hopes to soon begin a program that will allow expedited patent application for a $4,000 surcharge. Using the program could reduce application processing time to a ...

Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...

MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...

Fast-track examinations of planning permission applications for medium-risk projects are now going ahead, Interior Minister Constantinos Ioannou said on Tuesday. The announcement follows the ...